Neurocrine Adds Four Gene Therapies to Pipeline with Voyager Collaboration
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 2 (Table of Contents)
Published: 6 Feb-2019
DOI: 10.3833/pdr.v2019.i2.2402 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Expanding its pipeline of gene therapies for neurological disorders, Neurocrine Biosciences has partnered up with Voyager Therapeutics to develop and commercialise four of Voyager’s gene therapy programmes – VY-AADC for Parkinson’s disease (PD) and VY-FXN01 for Friedreich’s ataxia (FA) as well as rights to two programmes to be determined...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS